Balyasny Asset Management
IBB icon

Balyasny Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Balyasny Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$5.06M – 3175
2025
Q4 		$5.06M Buy
+30,000
New +$4.87M 0.01% 1388
2025
Q2 		– Sell
-15,500
Closed -$1.98M – 3060
2025
Q1 		$1.98M Sell
15,500
-324,100
-95% -$43.9M ﹤0.01% 1704
2024
Q4 		$44.9M Buy
339,600
+88,500
+35% +$12.4M 0.07% 356
2024
Q3 		$36.6M Buy
251,100
+1,100
+0.4% +$159K 0.06% 413
2024
Q2 		$34.3M Sell
250,000
-26,900
-10% -$3.59M 0.06% 412
2024
Q1 		$38M Buy
276,900
+26,900
+11% +$3.67M 0.07% 400
2023
Q4 		$34M Sell
250,000
-67,000
-21% -$8.17M 0.06% 392
2023
Q3 		$38.8M Buy
+317,000
New +$40.3M 0.08% 346
2021
Q2 		– Sell
-273,000
Closed -$41.1M – 2132
2021
Q1 		$41.1M Buy
273,000
+218,000
+396% +$34.6M 0.2% 116
2020
Q4 		$8.33M Buy
+55,000
New +$7.86M 0.05% 490
2020
Q1 		– Sell
-150,000
Closed -$18.1M – 1306
2019
Q4 		$18.1M Sell
150,000
-150,000
-50% -$16.7M 0.11% 283
2019
Q3 		$29.9M Buy
300,000
+200,000
+200% +$20.9M 0.21% 143
2019
Q2 		$10.9M Buy
100,000
+75,000
+300% +$7.98M 0.07% 386
2019
Q1 		$2.79M Buy
+25,000
New +$2.74M 0.02% 732
2018
Q1 		– Sell
-195,000
Closed -$20.8M – 2103
2017
Q4 		$20.8M Buy
195,000
+135,000
+225% +$14.4M 0.07% 392
2017
Q3 		$6.67M Sell
60,000
-45,000
-43% -$4.81M 0.03% 625
2017
Q2 		$10.9M Buy
105,000
+45,000
+75% +$4.43M 0.04% 518
2017
Q1 		$5.87M Sell
60,000
-90,000
-60% -$8.62M 0.03% 658
2016
Q4 		$13.3M Buy
+150,000
New +$13.7M 0.07% 395
2015
Q1 		– Sell
-375,000
Closed -$37.9M – 1004
2014
Q4 		$37.9M Buy
+375,000
New +$36.4M 0.35% 72

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's IBB Position: Q1 2025 in Review

Balyasny Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 35,859 shares — an estimated $4.86M sold.

Balyasny Asset Management first reported a position in IBB in Q3 2021 and held it in 9 quarters. The position peaked at $20.8M in Q3 2021. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

  • Balyasny Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 35,859 iShares Biotechnology ETF shares in Q1 2025, an estimated $4.86M.
  • Balyasny Asset Management first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 9 quarters.
  • Balyasny Asset Management's iShares Biotechnology ETF position peaked at $20.8M in Q3 2021.
  • 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.